HTF Market Intelligence released a new research report of 190 pages on title ‘Women Infertility – Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies.
The Pharmaceutical and Healthcare disease pipeline guide Women Infertility – Pipeline Review, H1 2017, provides an overview of the Women Infertility (Women’s Health) pipeline landscape.
Infertility is the inability to get pregnant after a year of unprotected intercourse. Female infertility can be also be caused by a number of factors, which include damage to fallopian tubes, hormonal causes, cervical causes, uterine causes, unexplained infertility. Treatment depends on the cause of infertility.
Request a sample report @ https://www.htfmarketreport.com/sample-report/321994-women-infertility-pipeline-review
Pharmaceutical and Healthcare latest pipeline guide Women Infertility – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Women Infertility (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Women Infertility (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 14, 14, 1, 28, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.
Women Infertility (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women’s Health).
– The pipeline guide reviews pipeline therapeutics for Women Infertility (Women’s Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Women Infertility (Women’s Health) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Women Infertility (Women’s Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women’s Health)
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Global Markets Direct Report Coverage 8
Women Infertility – Overview 9
Women Infertility – Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 20
Women Infertility – Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Women Infertility – Companies Involved in Therapeutics Development 31
4P Therapeutics LLC 31
AbbVie Inc 31
Addex Therapeutics Ltd 32
AlphaMab Co Ltd 32
APAvadis Biotechnologies Srl 33
ASKA Pharmaceutical Co Ltd 33
Astellas Pharma Inc 34
Bayer AG 34
Dong-A Socio Holdings Co Ltd 35
Dongkook Pharmaceutical Co Ltd 36
ElexoPharm GmbH 36
EndoCeutics Inc 37
Enteris BioPharma Inc 37
Evotec AG 38
Ferring International Center SA 38
Forendo Pharma Ltd 39
Glycotope GmbH 39
Isifer AB 40
Kissei Pharmaceutical Co Ltd 40
Lipicard Technologies Ltd 41
Livzon Pharmaceutical Group Inc 41
Luye Pharma Group Ltd 42
Merck & Co Inc 42
Navya Biologicals Pvt Ltd 43
Nippon Shinyaku Co Ltd 43
Nora Therapeutics Inc 44
ObsEva SA 44
Ogeda SA 45
…….View Complete table of contents @ https://www.htfmarketreport.com/reports/321994-women-infertility-pipeline-review
Companies Mentioned in the Report
4P Therapeutics LLC
Addex Therapeutics Ltd
AlphaMab Co Ltd
APAvadis Biotechnologies Srl
ASKA Pharmaceutical Co Ltd
Astellas Pharma Inc
Dong-A Socio Holdings Co Ltd
Dongkook Pharmaceutical Co Ltd
Enteris BioPharma Inc
Ferring International Center SA
Forendo Pharma Ltd
Kissei Pharmaceutical Co Ltd
Lipicard Technologies Ltd
Livzon Pharmaceutical Group Inc
Luye Pharma Group Ltd
Merck & Co Inc
Navya Biologicals Pvt Ltd
Nippon Shinyaku Co Ltd
Nora Therapeutics Inc
Orphagen Pharmaceuticals Inc
Pangen Biotech Inc.
Pantec Biosolutions AG
Repros Therapeutics Inc
Richter Gedeon Nyrt
SK Chemicals Co Ltd
Takeda Pharmaceutical Company Ltd
Zydus Cadila Healthcare Ltd
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=321994
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women’s Health).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Women Infertility (Women’s Health) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Make an enquiry before buying this Report @ https://www.htfmarketreport.com/enquiry-before-buy/321994-women-infertility-pipeline-review
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218